SCHEMBL5160738

SCHEMBL5160738

CNC(=O)CC(=O)c1ncc[nH]1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
KMT2A Q03164 1/20 0.38
ALDH1A1 P00352 2/20 0.35
KDM4E B2RXH2 1/20 0.35
BRAF P15056 1/20 0.35
HDAC1 Q13547 1/20 0.35
HSPA5 P11021 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.33
MMP1 P03956 1/20 0.33
MMP3 P08254 1/20 0.33
MMP7 P09237 1/20 0.33
HSP90AB1 P08238 1/20 0.33
HTR1A P08908 1/20 0.33
TAAR1 Q96RJ0 1/20 0.33
TBXAS1 P24557 1/20 0.33
GLA P06280 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29163121 0.85 NPC1 (0.47) NPC1RAB9AKMT2AALDH1A1KDM4E
SCHEMBL5159778 0.83 NPC1 (0.41) NPC1RAB9AKMT2AALDH1A1KDM4E
SCHEMBL31602536 0.80 NPC1 (0.45) NPC1RAB9AKMT2AALDH1A1KDM4E
SCHEMBL743343 0.79 NPC1 (0.43) NPC1RAB9AKMT2AALDH1A1KDM4E
SCHEMBL2321138 0.79
SCHEMBL5160052 0.79 NPC1 (0.44) NPC1RAB9AKMT2AALDH1A1KDM4E
SCHEMBL5468184 0.79 NPC1 (0.44) NPC1RAB9AKMT2AALDH1A1KDM4E
SCHEMBL5163628 0.78 NPC1 (0.42) NPC1RAB9AKMT2AALDH1A1KDM4E
SCHEMBL5161632 0.77 NPC1 (0.42) NPC1RAB9AKMT2AALDH1A1KDM4E
Hydrochloric Acid SCHEMBL26916941 0.77 NPC1 (0.49) NPC1RAB9AKMT2AALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293899-B2 Ketone transfer hydrogenation of stereoisomerically enriched 3-heteroaryl-3-oxocarboxylic esters by reducing 3-heteroaryl-3-hydroxycarboxylic esters in the presence of a ruthenium-containing catalyst, an amine and formic acid and/or formates LANXESS DEUTSCHLAND GMBH (DE) 2012-10-23 US disclosed
EP-1340746-B1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives SALTIGO GMBH (DE) 2007-02-28 EP disclosed
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives LANXESS DEUTSCHLAND GMBH (DE) 2003-12-04 US disclosed
EP-1340746-A1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives BAYER AG (DE) 2003-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives GRHPR, HPD, HAAO NPC1 2400/4885RAB9A 3428/4885KMT2A 1666/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.